Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Quinine dihydrochloride
Drug ID BADD_D01896
Description An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Indications and Usage For the treatment of malaria and leg cramps
Marketing Status approved
ATC Code P01BC01
DrugBank ID DB00468
KEGG ID D08461
MeSH ID D011803
PubChem ID 91429
TTD Drug ID D03DDR
NDC Product Code 65162-811
UNII 8C3EMH7D9X
Synonyms Quinine | Quinimax | Quinine Bisulfate | Bisulfate, Quinine | Quinine Hydrochloride | Hydrochloride, Quinine | Myoquin | Quinamm | Quinbisan | Legatrim | Quinine Lafran | Quinine Sulfate | Sulfate, Quinine | Quinine Sulphate | Sulphate, Quinine | Quinine-Odan | Quinoctal | Surquina | Biquinate | Strema | Quindan | Quinbisul | Quinson | Quinsul
Chemical Information
Molecular Formula C20H26Cl2N2O2
CAS Registry Number 60-93-5
SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Night blindness06.02.10.010; 14.12.03.001--
Oesophagitis07.08.05.001--
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.002--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Palpitations02.11.04.012--
Pancytopenia01.03.03.003--Not Available
Petechiae23.06.01.003; 01.01.03.002; 24.07.06.004--Not Available
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Plasmodium falciparum infection11.06.04.003; 01.03.02.012--Not Available
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Sudden visual loss06.02.10.011; 17.17.01.014--Not Available
Syncope17.02.04.008; 24.06.02.012; 02.11.04.015--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombotic thrombocytopenic purpura23.06.01.011; 01.08.01.005; 24.07.06.014--
Tinnitus17.04.07.004; 04.04.01.002--
Torsade de pointes02.03.04.005--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages